Department of Public Health and Infectious Diseases, Laboratory Affiliated to Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, Rome, Italy.
Center For Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, Rome, Italy.
FASEB J. 2021 Feb;35(2):e21358. doi: 10.1096/fj.202001885RR.
Treatment of respiratory viral infections remains a global health concern, mainly due to the inefficacy of available drugs. Therefore, the discovery of novel antiviral compounds is needed; in this context, antimicrobial peptides (AMPs) like temporins hold great promise. Here, we discovered that the harmless temporin G (TG) significantly inhibited the early life-cycle phases of influenza virus. The in vitro hemagglutinating test revealed the existence of TG interaction with the viral hemagglutinin (HA) protein. Furthermore, the hemolysis inhibition assay and the molecular docking studies confirmed a TG/HA complex formation at the level of the conserved hydrophobic stem groove of HA. Remarkably, these findings highlight the ability of TG to block the conformational rearrangements of HA2 subunit, which are essential for the viral envelope fusion with intracellular endocytic vesicles, thereby neutralizing the virus entry into the host cell. In comparison, in the case of parainfluenza virus, which penetrates host cells upon a membrane-fusion process, addition of TG to infected cells provoked ~1.2 log reduction of viral titer released in the supernatant. Nevertheless, at the same condition, an immunofluorescent assay showed that the expression of viral hemagglutinin/neuraminidase protein was not significantly reduced. This suggested a peptide-mediated block of some late steps of viral replication and therefore the impairment of the extracellular release of viral particles. Overall, our results are the first demonstration of the ability of an AMP to interfere with the replication of respiratory viruses with a different mechanism of cell entry and will open a new avenue for the development of novel therapeutic approaches against a large variety of respiratory viruses, including the recent SARS-CoV2.
治疗呼吸道病毒感染仍然是全球健康关注的焦点,主要是因为现有药物的疗效不佳。因此,需要发现新的抗病毒化合物;在这种情况下,像 temporin 这样的抗菌肽 (AMP) 具有很大的潜力。在这里,我们发现无害的 temporin G (TG) 能显著抑制流感病毒的早期生命周期阶段。体外血凝试验显示 TG 与病毒血凝素 (HA) 蛋白存在相互作用。此外,溶血抑制试验和分子对接研究证实了 TG/HA 复合物在 HA 的保守疏水性茎槽水平上形成。值得注意的是,这些发现强调了 TG 阻断 HA2 亚基构象重排的能力,这对于病毒包膜与细胞内内吞小泡融合至关重要,从而中和了病毒进入宿主细胞。相比之下,在副流感病毒通过膜融合过程穿透宿主细胞的情况下,向感染细胞中添加 TG 会导致上清液中释放的病毒滴度减少约 1.2 个对数。然而,在相同条件下,免疫荧光检测显示病毒血凝素/神经氨酸酶蛋白的表达没有明显减少。这表明肽介导了病毒复制的一些晚期步骤的阻断,从而损害了病毒颗粒的细胞外释放。总的来说,我们的结果首次证明了 AMP 能够以不同的细胞进入机制干扰呼吸道病毒的复制,并将为开发针对包括最近的 SARS-CoV2 在内的多种呼吸道病毒的新型治疗方法开辟新途径。